NZ516637A - System for microvolume laser scanning cytometry - Google Patents
System for microvolume laser scanning cytometryInfo
- Publication number
- NZ516637A NZ516637A NZ516637A NZ51663700A NZ516637A NZ 516637 A NZ516637 A NZ 516637A NZ 516637 A NZ516637 A NZ 516637A NZ 51663700 A NZ51663700 A NZ 51663700A NZ 516637 A NZ516637 A NZ 516637A
- Authority
- NZ
- New Zealand
- Prior art keywords
- particles
- sample
- pixel values
- light
- cell
- Prior art date
Links
- 238000004163 cytometry Methods 0.000 title claims description 17
- 239000002245 particle Substances 0.000 claims abstract description 58
- 238000001514 detection method Methods 0.000 claims abstract description 44
- 238000004458 analytical method Methods 0.000 claims abstract description 24
- 230000005284 excitation Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- 238000003556 assay Methods 0.000 claims description 25
- 230000003287 optical effect Effects 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 14
- 238000004422 calculation algorithm Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 238000007405 data analysis Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims 11
- 238000005286 illumination Methods 0.000 claims 3
- 239000000090 biomarker Substances 0.000 abstract description 45
- 239000013060 biological fluid Substances 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 3
- 238000004621 scanning probe microscopy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 144
- 239000000523 sample Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 230000004907 flux Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- -1 antibodies Proteins 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108010004469 allophycocyanin Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 239000002359 drug metabolite Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000012362 drug development process Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 229910004338 Ti-S Inorganic materials 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1484—Optical investigation techniques, e.g. flow cytometry microstructural devices
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- Multimedia (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Evolutionary Computation (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14479899P | 1999-07-21 | 1999-07-21 | |
| PCT/US2000/011133 WO2001008081A1 (fr) | 1999-07-21 | 2000-04-26 | Systeme de cytometrie par balayage, a laser de microvolume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ516637A true NZ516637A (en) | 2003-08-29 |
Family
ID=22510184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ516637A NZ516637A (en) | 1999-07-21 | 2000-04-26 | System for microvolume laser scanning cytometry |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1203339A4 (fr) |
| JP (1) | JP2003505707A (fr) |
| KR (1) | KR20020013970A (fr) |
| AU (1) | AU4491100A (fr) |
| CA (1) | CA2379836A1 (fr) |
| MX (1) | MXPA01013398A (fr) |
| NZ (1) | NZ516637A (fr) |
| WO (1) | WO2001008081A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192778B2 (en) | 1999-10-06 | 2007-03-20 | Natan Michael J | Surface enhanced spectroscopy-active composite nanoparticles |
| US8497131B2 (en) | 1999-10-06 | 2013-07-30 | Becton, Dickinson And Company | Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules |
| WO2002079764A1 (fr) | 2001-01-26 | 2002-10-10 | Nanoplex Technologies, Inc. | Nanoparticules sandwich a spectrometrie active exaltees de surface |
| AU2001292894A1 (en) | 2000-09-20 | 2002-04-02 | Surromed, Inc. | Method for monitoring resting and activated platelets in unfixed blood samples |
| US7572642B2 (en) | 2001-04-18 | 2009-08-11 | Ambrigen, Llc | Assay based on particles, which specifically bind with targets in spatially distributed characteristic patterns |
| WO2002090947A2 (fr) * | 2001-05-07 | 2002-11-14 | Deutsches Krebsforschungszentrum Stiftung D. Öffentl. Rechts | Microscope pour analyse de la fluctuation de fluorescence et module de mesure ou module de balayage de la fluctuation de fluorescence et procede de mesure de la fluctuation de fluorescence ainsi que procede et dispositif d'alignement d'un microscope pour analyse de la fluctuation de fluorescence |
| WO2006125674A1 (fr) * | 2005-05-25 | 2006-11-30 | Stiftelsen Universitetsforskning Bergen | Systeme de microscope et procede de criblage de medicaments, physiotherapies et biorisques |
| US8409863B2 (en) | 2005-12-14 | 2013-04-02 | Becton, Dickinson And Company | Nanoparticulate chemical sensors using SERS |
| US7796251B2 (en) * | 2006-03-22 | 2010-09-14 | Itt Manufacturing Enterprises, Inc. | Method, apparatus and system for rapid and sensitive standoff detection of surface contaminants |
| JP4909254B2 (ja) * | 2007-12-26 | 2012-04-04 | 日本電信電話株式会社 | 浮遊粒子状物質測定装置 |
| JP5550719B2 (ja) * | 2009-04-27 | 2014-07-16 | イーアイ・スペクトラ・エルエルシー | ピペット機器 |
| US9746412B2 (en) | 2012-05-30 | 2017-08-29 | Iris International, Inc. | Flow cytometer |
| CN104641217B (zh) * | 2012-05-30 | 2019-02-22 | 艾瑞斯国际有限公司 | 流式细胞仪 |
| JP7201297B2 (ja) * | 2018-09-26 | 2023-01-10 | シスメックス株式会社 | フローサイトメーター、データ送信方法及び情報処理システム |
| US20220074845A1 (en) * | 2019-01-03 | 2022-03-10 | Pixcell Medical Technologies Ltd. | Systems and methods for analyzing a fluid sample |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455646B (sv) * | 1984-10-22 | 1988-07-25 | Radians Innova Ab | Fluorescensanordning |
| US5107422A (en) * | 1989-10-02 | 1992-04-21 | Kamentsky Louis A | Method and apparatus for measuring multiple optical properties of biological specimens |
| US5127730A (en) * | 1990-08-10 | 1992-07-07 | Regents Of The University Of Minnesota | Multi-color laser scanning confocal imaging system |
| JPH0599912A (ja) * | 1991-10-11 | 1993-04-23 | Union Shokai:Kk | アナログフイルター装置 |
| AU671984B2 (en) * | 1992-02-18 | 1996-09-19 | Neopath, Inc. | Method for identifying objects using data processing techniques |
| US5377003A (en) * | 1992-03-06 | 1994-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Spectroscopic imaging device employing imaging quality spectral filters |
| US5889881A (en) * | 1992-10-14 | 1999-03-30 | Oncometrics Imaging Corp. | Method and apparatus for automatically detecting malignancy-associated changes |
| US5556764A (en) * | 1993-02-17 | 1996-09-17 | Biometric Imaging, Inc. | Method and apparatus for cell counting and cell classification |
| US5456252A (en) * | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
| JP3474612B2 (ja) * | 1993-12-03 | 2003-12-08 | 浜松ホトニクス株式会社 | 光検出装置 |
| JPH08313348A (ja) * | 1995-05-16 | 1996-11-29 | Kanagawa Kagaku Gijutsu Akad | 赤外光時間応答測定装置 |
| US5582705A (en) * | 1995-05-19 | 1996-12-10 | Iowa State University Research Foundation, Inc. | Multiplexed capillary electrophoresis system |
-
2000
- 2000-04-26 JP JP2001513096A patent/JP2003505707A/ja active Pending
- 2000-04-26 CA CA002379836A patent/CA2379836A1/fr not_active Abandoned
- 2000-04-26 KR KR1020027000806A patent/KR20020013970A/ko not_active Application Discontinuation
- 2000-04-26 AU AU44911/00A patent/AU4491100A/en not_active Abandoned
- 2000-04-26 EP EP00926370A patent/EP1203339A4/fr not_active Withdrawn
- 2000-04-26 NZ NZ516637A patent/NZ516637A/en unknown
- 2000-04-26 WO PCT/US2000/011133 patent/WO2001008081A1/fr active IP Right Grant
- 2000-04-26 MX MXPA01013398A patent/MXPA01013398A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001008081A1 (fr) | 2001-02-01 |
| EP1203339A4 (fr) | 2006-09-13 |
| JP2003505707A (ja) | 2003-02-12 |
| AU4491100A (en) | 2001-02-13 |
| KR20020013970A (ko) | 2002-02-21 |
| EP1203339A1 (fr) | 2002-05-08 |
| CA2379836A1 (fr) | 2001-02-01 |
| MXPA01013398A (es) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7336812B2 (en) | System for microvolume laser scanning cytometry | |
| JP4215397B2 (ja) | 多重分析物診断システム | |
| US8660332B2 (en) | Blood and cell analysis using an imaging flow cytometer | |
| US6350613B1 (en) | Determination of white blood cell differential and reticulocyte counts | |
| JP2019109249A (ja) | 生物学的状態を検出するシステムおよび方法 | |
| NZ516637A (en) | System for microvolume laser scanning cytometry | |
| US20090003681A1 (en) | Blood and cell analysis using an imaging flow cytometer | |
| US20030096324A1 (en) | Methods for differential cell counts including related apparatus and software for performing same | |
| JP2005502872A (ja) | 光バイオディスクシステムを使用した、核の形態に基づく白血球の型の識別および定量 | |
| Bachar et al. | An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology | |
| KR20080034012A (ko) | 마이크로입자를 분류하는 방법과 데이터 구조 및 시스템 | |
| US20230332999A1 (en) | Specimen analysis system and specimen analysis method | |
| CN112161913A (zh) | 一种用于流式荧光分析系统的分析方法及设备 | |
| US20230296591A1 (en) | Sample analysis method, sample analyzer, and computer-readable storage medium | |
| US8349256B2 (en) | Blood cell analyzer, blood cell analyzing method, and computer program product | |
| Pierzchalski et al. | Introduction A: Recent advances in cytometry instrumentation, probes, and methods | |
| US11592367B2 (en) | Method for analyzing and selecting a specific droplet among a plurality of droplets and associated apparatus | |
| Norton et al. | Cell enumeration and characterization in microvolume laser scanning cytometry: a multicolor image-processing package | |
| US20240029458A1 (en) | A method for automated determination of platelet count based on microscopic images of peripheral blood smears | |
| Leary | Cytometry of Single-Cells for Biology and Biomedicine | |
| Tárnok et al. | Immunophenotyping using a laser scanning cytometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |